Scarica l'app Stockscreener
810.24
0.53%
4.31
Dopo l'orario di chiusura:
810.50
0.26
+0.03%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Precedente Chiudi:
$805.93
Aprire:
$814
Volume 24 ore:
614.85K
Relative Volume:
0.64
Capitalizzazione di mercato:
$83.42B
Reddito:
$14.92B
Utile/perdita netta:
$4.42B
Rapporto P/E:
19.74
EPS:
41.0422
Flusso di cassa netto:
$3.79B
1 W Prestazione:
+1.66%
1M Prestazione:
+19.74%
6M Prestazione:
+2.28%
1 anno Prestazione:
+41.18%
Intervallo 1D:
$805.93
$821.02
Intervallo di 1 settimana:
$784.61
$821.02
Portata 52W:
$541.00
$821.11
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Nome
Regeneron Pharmaceuticals Inc
Settore
Industria
Telefono
(914) 847-7000
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
810.24 | 82.97B | 14.92B | 4.42B | 3.79B | 41.04 |
VRTX
Vertex Pharmaceuticals Inc
|
528.19 | 130.67B | 12.34B | 4.34B | 3.71B | 16.87 |
ARGX
Argen X Se Adr
|
992.99 | 61.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
216.00 | 45.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
369.15 | 41.01B | 5.76B | 514.49M | 1.10B | 4.4813 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-31 | Ripresa | Piper Sandler | Overweight |
| 2026-03-06 | Iniziato | Barclays | Overweight |
| 2026-01-07 | Aggiornamento | BofA Securities | Underperform → Buy |
| 2025-12-03 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | Iniziato | HSBC Securities | Buy |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Perform |
| 2025-08-14 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Downgrade | Argus | Buy → Hold |
| 2025-05-30 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Downgrade | UBS | Buy → Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Iniziato | Bernstein | Outperform |
| 2024-01-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Reiterato | Oppenheimer | Perform |
| 2023-06-28 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-23 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2023-01-20 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Aggiornamento | Jefferies | Underperform → Hold |
| 2022-09-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-12-07 | Ripresa | Cowen | Market Perform |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Ripresa | BMO Capital Markets | Outperform |
| 2021-11-05 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-01-25 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-10-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-05-26 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-17 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Iniziato | The Benchmark Company | Hold |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-11 | Aggiornamento | Argus | Hold → Buy |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-16 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Hold |
| 2019-11-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
Mostra tutto
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Promising Biotech Stocks To Watch TodayAugust 18th - MarketBeat
REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action LawsuitInvestors With Losses May Contact The Gross Law Firm - PR Newswire
Regeneron ends eye disease study due to antibody’s safety profile - BioSpace
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Regeneron Pharmaceuticals, Inc. (REGN) - TMX Newsfile
Regeneron ends eye disease study after antibody shows ‘unfavorable’ risk/benefit profile - BioSpace
REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Resilient Regeneron stock trades close to 52-week high as dividend and earnings support valuation - AD HOC NEWS
UNIVEST FINANCIAL Corp Takes $8.15 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action LawsuitHagens Berman Sobol Shapiro LLP - PR Newswire
Perigon Wealth Management LLC Takes Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Invests $160.53 Million in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron halts early-stage uveitis trial after safety event - The Pharma Letter
4,376 Shares in Regeneron Pharmaceuticals, Inc. $REGN Purchased by Citizens Financial Group Inc. RI - MarketBeat
Deutsche Bank AG Makes New $323.25 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Grandfield & Dodd LLC Purchases Shares of 36,628 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
BlackRock Inc. Makes New $5.68 Billion Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
4,778 Shares in Regeneron Pharmaceuticals, Inc. $REGN Bought by B & T Capital Management DBA Alpha Capital Management - MarketBeat
Samsung Biologics? No — Samchundang Pharm Reaches Landmark Settlement in Eylea Biosimilar Patent Dispute, Clearing Path for Global Commercialization - finance.biggo.com
Regeneron Pharmaceuticals, Inc. Notice of September 14, - globenewswire.com
Resilient Regeneron stock hovers near 52-week high after dividend and analyst target hike - AD HOC NEWS
REGN UPCOMING DEADLINE: Levi & Korsinsky Alerts Regeneron - GlobeNewswire
Biotech Stocks To ResearchAugust 17th - MarketBeat
Can Regeneron Pharmaceuticals (NASDAQ:REGN) Extend Its Run? - Kalkine Media
REGN Investors Have Opportunity to Lead Regeneron - GlobeNewswire
REGN Maintained by Leerink Partners -- Price Target Raised to $8 - GuruFocus
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $824.00 at Leerink Partners - MarketBeat
Leerink Partners Adjusts PT on Regeneron Pharmaceuticals to $824 From $641, Maintains Market Perform Rating - marketscreener.com
Plato Investment Management Ltd Makes New $2.47 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Oppenheimer Asset Management Inc. Takes $1.50 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Focus Partners Advisor Solutions LLC Invests $1.35 Million in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
AMG National Trust Bank Makes New $1.22 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Bronstein, Gewirtz & Grossman LLC Urges Regeneron - GlobeNewswire
REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
USA Financial Formulas Acquires New Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
ETFs Investing in Regeneron Pharmaceuticals, Inc. Stocks - TradingView
7,506 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Summit Global Investments - MarketBeat
How Securities Lawsuits Over Trial Disclosures Will Impact Regeneron Pharmaceuticals’ (REGN) Pipeline-Driven Investment Story - simplywall.st
Wall Street Zen Upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Strong-Buy - MarketBeat
REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk) - fool.com
Is Biohaven (BHVN)’s Latest Regeneron Pharmaceuticals (REGN) Deal a Major Catalyst for its Pipeline? - finance.yahoo.com
Bernstein Lifts Regeneron Price Target to $756, Stays on Sidelines - finance.biggo.com
If You Invested $1000 In Regeneron Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today - Benzinga
Regeneron Genetics Center's Andy Deubler: The AI-Era Genomics Race Will Be Decided by Curation, Not Volume - finance.biggo.com
The Gross Law Firm Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class ... - Caledonian Record
Bernstein raises Regeneron stock price target to $756 on Eylea beat - Investing.com
BMS builds big in Texas; Regeneron backs would-be rival - Pharma Voice
Bernstein Adjusts PT on Regeneron Pharmaceuticals to $756 From $753, Maintains Market Perform Rating - marketscreener.com
Regeneron's Gene Therapy For Genetic Hearing Loss Gets Accelerated FDA Nod — Drug Pricing Deal With White House To Be Announced Today - Stocktwits
REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Regeneron Pharmaceuticals Inc Azioni (REGN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Guarini Kathryn | Director |
Aug 10 '26 |
Sale |
800.00 |
400 |
320,000 |
603 |
| Zoghbi Huda Y | Director |
Aug 10 '26 |
Option Exercise |
376.69 |
800 |
301,352 |
2,503 |
| Zoghbi Huda Y | Director |
Aug 10 '26 |
Sale |
800.00 |
800 |
640,000 |
1,703 |
0.52%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):